What Is Sunvozertinib (Zegfrovy)? FDA Approval, Licensing in Türkiye, and Reimbursement Status

• FDA Approval: Yes (first approval: 2 July 2025)
• Brand Name: Zegfrovy
• Active Ingredient: Sunvozertinib
• Administration: Oral tablet (200 mg 1 time daily, with food)
• Class: Irreversible EGFR tyrosine kinase inhibitor (EGFR TKI)
• Category: Targeted drug / Oncology agent
• Manufacturer: Dizal Pharmaceutical / Jiangsu Hengrui Pharmaceuticals
• Distribution in Türkiye: Not yet licensed in Türkiye.
• Approved Cancer Indications: Non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation, progressing after platinum-based chemotherapy

What Is Sunvozertinib, and How Does It Work?

Sunvozertinib (brand name Zegfrovy) is an oral, covalently binding, selective tyrosine kinase inhibitor (TKI) used for locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene.

Sunvozertinib received accelerated FDA approval on 2 July 2025. It is indicated for adults with NSCLC carrying an EGFR exon 20 insertion (ex20ins) mutation detected by an FDA-approved test, whose disease progressed after platinum-based chemotherapy.

How Does It Work?

Sunvozertinib is an irreversible kinase inhibitor selectively developed against EGFR exon 20 insertion mutations. Its molecular mechanism can be explained as follows:

• EGFR activation and mutations: EGFR is a cell-surface receptor tyrosine kinase. Ligand binding activates it, initiating cell proliferation, differentiation, and survival pathways (RAS/RAF/MEK/ERK and PI3K/AKT/mTOR).
• Exon 20 insertion mutations occur within or after EGFR's C-helix, causing ligand-independent conformational activation. They make EGFR constitutively active and stimulate proliferation.
• How sunvozertinib binds: Sunvozertinib covalently (irreversibly) binds the mutated EGFR tyrosine kinase domain. Specifically, covalent binding at C797 blocks the ATP-binding pocket and inhibits phosphorylation. This interrupts EGFR signaling and prevents tumor cell proliferation and survival.
• Selectivity and advantages: Sunvozertinib has lower affinity for wild-type EGFR, potentially reducing off-target effects such as skin and gastrointestinal toxicity. Unlike other EGFR TKIs, it was specifically developed for exon 20 insertion mutations, which resist conventional TKIs such as erlotinib and gefitinib.

FDA (US Food and Drug Administration) Approval History

• 2 July 2025: FDA granted accelerated approval to ZEGFROVY (sunvozertinib) for NSCLC with EGFR exon 20 insertion mutations.
• 7 January 2025: the US FDA granted priority review to Dizal's new drug application (NDA) for sunvozertinib.
• 8 November 2024: Dizal submitted an FDA new drug application for sunvozertinib in relapsed or refractory NSCLC with EGFR exon 20 insertion mutations.
• 7 April 2024: FDA granted Breakthrough Therapy Designation to sunvozertinib for first-line treatment of advanced NSCLC with EGFR exon 20 insertion mutations.

Licensing in Türkiye

Not yet licensed in Türkiye.

Resistance Mechanisms

Secondary Changes in the Target Mutation: Sunvozertinib covalently binds EGFR's C797 residue. Mutations preventing this binding may develop:

• EGFR C797S mutation: this alters the catalytic pocket (ATP-binding pocket) where sunvozertinib binds. EGFR C797S prevents covalent binding and eliminates irreversible inhibition. This has also been observed with 3rd-generation EGFR TKIs such as osimertinib.

Activation of alternative non-EGFR pathways: when EGFR is suppressed, the tumor may activate other proliferation pathways:

• MET amplification: MET signaling bypasses EGFR to maintain cell growth.
• HER2 amplification: HER2/MAPK pathways may be activated.
• KRAS mutations: downstream KRAS mutations enable signaling independently of EGFR.
• PIK3CA mutation or PTEN loss: independent PI3K/AKT/mTOR activation may produce resistance.

Phenotypic Change (Histological Transformation): squamous cell transformation or transformation to small cell lung cancer has been described as a resistance mechanism after certain EGFR TKIs. This fundamentally changes treatment sensitivity.

Pharmacokinetic Resistance (Factors Affecting Drug Levels): Reduced drug absorption (gastrointestinal problems), Increased drug metabolism (CYP enzyme induction), Increased multidrug efflux pumps (e.g., ABCB1/MDR1, BCRP): may lower intracellular drug concentrations.

Absorption

• Oral bioavailability: high.
• Time to maximum plasma concentration (/sub>) (Tmax/sub&g): reached in approximately 4–6 hours on average (after a daily oral 200 mg dose).
• Food effect: absorption increases with food, so sunvozertinib should be taken with food.
• Dose-related increase: C<sub>max</sub&g and AUC (area under the curve) increase proportionally with dose.

Distribution

• Volume of distribution (V_d): approximately 200–300 L on average, indicating good distribution into extravascular tissues.
• Plasma protein binding: high, approximately 98%.
• Mainly binds carrier proteins such as albumin and alpha-1-acid glycoprotein.

Metabolism

• Main metabolizing enzyme: CYP3A4 isoenzyme
• Metabolic pathway: phase I reactions (hydroxylation, N-dealkylation) produce inactive metabolites.
• Important interactions: strong CYP3A4 inhibitors (e.g., ketoconazole) may increase plasma levels; strong CYP3A4 inducers (e.g., rifampicin) may reduce them.

Elimination

• Half-life (t_1/2): 50–60 hours on average. This long half-life allows dosing 1 time daily.
• Total clearance (CL): 4–6 L/hour on average
• Excretion: mainly through bile into feces (over 80%); urinary excretion below 5% — renal elimination is negligible. Most is excreted unchanged or as inactive metabolites.

Dosing Schedule

• The recommended dose is 200 mg 1 time daily. Take the tablet orally with food. Swallow it whole without chewing or crushing. Taking it at the same time each day is recommended.
• If a dose is missed and less than 12 hours have passed, it may be taken. If more than 12 hours have passed, skip that day's dose and resume normally the next day. Do not take two doses on the same day.
• Drug absorption takes place through the liver. Use cautiously in moderate or severe liver failure, adjusting the dose if needed. Because renal excretion is minimal, dose changes are generally unnecessary in mild-to-moderate renal failure.
• For serious adverse effects (e.g., severe diarrhea, rash, eye problems), treatment may be temporarily withheld. Once effects resolve, restart at a lower dose (first 150 mg/day, then 100 mg/day if needed). Recurrent adverse effects or intolerance may require permanent discontinuation.
• Continue until disease progression or inability to tolerate the drug.

Drug Interactions

CYP3A4 inhibitors (increase blood levels)Sunvozertinib is metabolized by hepatic CYP3A4. Drugs inhibiting this enzyme may raise blood levels and toxicity risk.

Examples:

• Ketoconazole
• Itraconazole
• Clarithromycin
• Ritonavir
• Verapamil
• Diltiazem

Recommendation: avoid strong CYP3A4 inhibitors. If essential, reducing the sunvozertinib dose may be necessary.

CYP3A4 inducers (reduce efficacy)

These drugs accelerate sunvozertinib breakdown, reducing blood levels and efficacy. Examples:

• Rifampicin
• Carbamazepine
• Phenytoin
• Phenobarbital
• St. John’s Wort (St. John's wort)

Recommendation: avoid concomitant use because sunvozertinib efficacy may be substantially reduced.

Drugs Affecting Gastric pH

Sunvozertinib solubility depends on gastric pH. Clinical studies, however, showed no marked interaction with acid suppressants such as proton pump inhibitors. Caution is still needed. Potential interacting drugs:

• Omeprazole
• Esomeprazole
• Ranitidine
• Antacids

Recommendation: no absolute contraindication, but caution with concurrent use. If an antacid is needed, take it at least 2 hours after sunvozertinib.

P-Glycoprotein (P-gp) Transporters

Sunvozertinib may be partly a P-gp substrate, but clinical significance is unclear. Very strong P-gp inhibitors or inducers pose a theoretical interaction risk.

Points Requiring Attention

Interstitial Lung Disease (ILD) / Pneumonia Risk

• Serious, potentially fatal interstitial lung disease (ILD) has been reported with EGFR inhibitors.
• Signs and symptoms: dry cough, shortness of breath, fever, interstitial infiltrates.
• Recommendation: stop treatment immediately if these symptoms develop, obtain imaging, and begin appropriate treatment (e.g., corticosteroids).

Severe Diarrhea

• Diarrhea was common and dose-dependent in clinical trials.
• Recommendation: encourage fluids and antidiarrheals (e.g., loperamide) if needed. Grade 3 or higher diarrhea may require dose reduction or a treatment break.

Skin Reactions

• EGFR's physiological role in skin means acneiform rash, itching, dryness, and erythema may develop.
• Recommendation: topical or systemic treatment may be started for skin reactions; consider dose reduction in severe cases.

Ocular Toxicity: 

• EGFR inhibitors may affect corneal epithelial cells, causing dry eyes, blurred vision, and conjunctivitis.
• Recommendation: refer for regular eye examinations to assess symptoms. Artificial tears or topical treatment may be started for complaints.

Liver Dysfunction

• Hepatic metabolism means drug levels may rise in moderate or severe liver failure.
• Recommendation: monitor liver enzymes before and regularly during treatment. Dose adjustment may be needed in moderate-to-severe hepatic impairment.

Drug Interactions (Through CYP3A4)

• Sunvozertinib is metabolized by CYP3A4.
• Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase toxicity.
• Strong inducers (e.g., rifampin) may reduce efficacy.
• Recommendation: avoid these drugs where possible or consider dose adjustment.

Pregnancy and Breastfeeding

• EGFR inhibitors are known to cause fetal toxicity in pregnancy.
• Recommendation: female patients should use effective contraception during treatment and for at least 1 week after the last dose. Breastfeeding is not recommended during treatment and for at least 1 week afterward.

QT Prolongation Risk (Rare)

• Preclinical data showed a potential QT prolongation risk.
• Recommendation: ECG monitoring is advised if used with drugs known to prolong QT.

Adverse Effects

Below are adverse effects and frequencies reported for sunvozertinib in clinical trials. Data come from the phase 1/2 WU-KONG1B study supporting FDA approval and other clinical evidence.

• Diarrhea 67%
• Rash (acneiform, maculopapular) 47%
• Elevated ALT 32%
• Nausea 31%
• Elevated AST 27%
• Elevated creatine phosphokinase (CPK) 25%
• Decreased appetite –28%
• Vomiting 23%
• Itching (pruritus) 23%
• Dry skin 22%
• Fatigue 20%
• Leukopenia 15%
• Hypophosphatemia 12%
• Severe diarrhea (Grade ≥3) 4%
• Severe rash (Grade ≥3) 3%
• Interstitial lung disease / Pneumonia 2%
• Ocular toxicity (blurred vision, dry eyes) 1–2%
• Hepatotoxicity (elevated AST/ALT) 1–2%